Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86.4 USD | +1.75% | +0.40% | +20.97% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 138M | Sales 2025 * | 157M | Capitalization | 1.55B |
---|---|---|---|---|---|
Net income 2024 * | 92M | Net income 2025 * | 50M | EV / Sales 2024 * | 11.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.86 x |
P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
26.8
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | +1.75% | ||
1 week | +0.40% | ||
Current month | +23.62% | ||
1 month | +21.69% | ||
3 months | +13.88% | ||
6 months | +43.78% | ||
Current year | +20.97% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 25 M€ | -2.72% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 86.4 | +1.75% | 160,612 |
24-05-23 | 84.91 | -2.72% | 125,663 |
24-05-22 | 87.28 | +0.32% | 111,767 |
24-05-21 | 87 | +0.43% | 171,725 |
24-05-20 | 86.63 | +0.66% | 105,186 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.97% | 1.55B | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- LGND Stock